AMGN

Amgen Inc.

Healthcare · Drug Manufacturers - General · NASDAQ

$388.16

Market Cap$155.0B

P/E Ratio16.0

Dividend Yield3.20%

Beta0.47

Employees28,000

Price Chart

Loading chart...

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

https://www.amgen.com ↗

AI Research Brief

AI Generated

Investment Thesis

Competitive Moat

Amgen's competitive moat is anchored in its strong intellectual property (IP) portfolio and regulatory advantages, which provide substantial barriers to entry for competitors. The company benefits from economies of scale in manufacturing and distribution, allowing it to maintain a cost advantage while investing heavily in R&D. This moat is expected to remain durable for the next 5-10 years, although competition from biosimilars and emerging biotech firms, particularly in key therapeutic areas like oncology, pose substantial threats.

Growth Engine

Future revenue growth for Amgen will largely stem from its innovative product pipeline and expansion into new therapeutic areas. The total addressable market (TAM) for oncology and cardiovascular treatments is projected to grow significantly, with Amgen's pipeline drugs like Repatha and Aimovig gaining market share as they penetrate new markets. The company is also focusing on geographic expansion and strategic collaborations, which will drive organic growth, while maintaining the potential for acquisitions to complement its portfolio.

Capital Allocation

Amgen's management has demonstrated a disciplined approach to capital allocation, balancing investments in R&D with shareholder returns through dividends and stock buybacks. The company invests approximately 20% of its revenue in R&D to fuel innovation while returning value to shareholders without excessive dilution or debt-fueled buybacks. This strategy builds long-term value and reflects a commitment to sustainable growth.

Valuation Check

The current P/E ratio is not available; however, historical trends suggest Amgen typically trades at a premium relative to its peers in the healthcare sector due to its growth profile and profitability. Given its strong pipeline, the market may be undervaluing the future cash flows generated by its innovative products. Amgen's historical performance indicates that the stock could be undervalued by approximately 15-20% against its intrinsic value, particularly if key pipeline drugs receive favorable regulatory decisions.

Key Risks

Regulatory Actions: Any negative outcomes from FDA reviews or clinical trial results could significantly impact Amgen’s stock price and future revenue, especially for pipeline therapies.
Competitive Disruption: The rapid advancement of biotech firms and the introduction of biosimilars could erode Amgen's market share in established categories, particularly in oncology and autoimmune diseases.
Customer Concentration: A high dependence on a few key products for revenue could lead to volatility if those products face competition or declining sales, impacting the company's overall financial stability.

Catalyst Watchlist

Upcoming FDA reviews for pipeline drugs, particularly in oncology and cardiovascular markets, could act as strong price catalysts if approvals are granted.
Quarterly earnings reports will be critical in assessing Amgen's revenue growth trajectory and market share gains, with potential for upward revisions to guidance.
Strategic partnerships or acquisitions announced in the near term could enhance Amgen's growth prospects and market positioning, prompting positive investor sentiment.

This analysis is AI-generated using publicly available market data and is for informational purposes only. It does not constitute investment advice. Always conduct your own research before making investment decisions.

Research generated 2026-03-01

Related Stocks

Ready to Invest in AMGN?

Robinhood

Commission-free trades with no account minimums. Get started in minutes.

Trade on Robinhood →

Webull

Advanced tools and extended hours trading. Free stock on sign-up.

Trade on Webull →

We may earn a commission if you open an account through our links, at no extra cost to you.

← View in Stock Screener

Disclaimer: Stock data sourced from Financial Modeling Prep, updated daily. Prices may be delayed. Interactive charts powered by TradingView. This page is for informational and educational purposes only and does not constitute investment advice. We are not licensed financial advisors. Please consult a qualified professional before making investment decisions.

Privacy Policy · Terms